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i. intrOdUCtiOn
 Among the many objectives of the American patent system is the promotion of 
innovation, which is accomplished by providing inventors with an incentive to 
invent.1 A patent provides this incentive by excluding anyone other than the patent 
holder from using the invention, among other things, for a limited period of time.2 A 
patent provides pharmaceutical companies with motivation to invest considerably in 
research and development.3 The grant of a patent, however, is subject to several 
statutory requirements, including that of “non-obviousness” under 35 U.S.C. § 103.4 
The purpose of the non-obviousness requirement is to prevent the issuance of a 
patent for something that is merely an obvious improvement on or variation of 
something already known.5 Should inventor B receive a patent for making a metallic 
1. The American patent system is a mix of incentives and restraints. Craig Allen Nard et al., The 
Law of Intellectual Property 655–66 (2d ed. 2008) [hereinafter Law of Intellectual 
Property]. The ultimate objective both “bestows benefits and impose[s] costs on society . . . .” Id. at 
655. The requirement to disclose the invention to the world provides society with the knowledge and 
means to innovate beyond what was already invented. Patent law offers a potential financial reward as 
an incentive to invent, disclosure of technical data, incentive to invest in developing the invention, and 
a means to facilitate efficiency through licensing. Id. at 656.
2. A patent gives its owner a right to exclude others from “making, using, offering for sale, or selling the 
invention throughout the United States or importing the invention into the United States.” Craig 
Allen Nard, The Law of Patents 1 (2008) [hereinafter Law of Patents] (quoting 35 U.S.C. § 154 
(2006)). A patent does not give its owner any positive rights, such as the right to make, use, or sell the 
invention. Id. The patent infringement statute states that “whoever without authority makes, uses, offers 
to sell, or sells any patented invention, within the United States or imports into the United States any 
patented invention during the term of the patent therefore, infringes the patent.” 35 U.S.C § 271(a). The 
term of the grant begins “on the date on which the patent issues and ending 20 years from the date on 
which the application for the patent was filed.” 35 U.S.C § 154(a)(2).
3. See Law of Patents, supra note 2, at 2–3. The incentive offered by patent protection is relied on 
differently by various industries. Some industries rely more on copyright and trademark law to protect 
their intellectual property. However, the pharmaceutical industry relies heavily on patent protection. Id. 
The total estimated cost to develop a new drug was $897 million in May 2003. Am. Bar Ass’n, 
Biotechnology and the Law 204 (Eileen Smith Ewing & High B. Wellons eds., 2007). 
4. 35 U.S.C. § 103. In addition, § 102 describes the statutory condition that the invention must be novel. 
Id. § 102. Section 112 is the specification statute, which restrains the claims to only what is disclosed 
and what the patent enables. Id. § 112. Section 101 pertains to the kinds of inventions that are eligible 
for patent protection, including the utility of the subject matter sought to be patented. Id. § 101. 
However, of all the statutory requirements, the most frequently litigated is non-obviousness. Non-
obviousness is described in §103, as follows:
A patent may not be obtained though the invention is not identically disclosed or 
described as set forth in section 102 of this title, if the differences between the subject 
matter sought to be patented and the prior art are such that the subject matter as a 
whole would have been obvious at the time the invention was made to a person having 
ordinary skill in the art to which said subject matter pertains. Patentability should not 
be negatived by the manner in which the invention was made.
 Id. § 103.
5. The test for novelty under  § 102 is confining in the sense that it requires that each and every limitation 
of the claimed invention be present in a single prior art source. Law of Intellectual Property, supra 
note 1, at 730. Non-obviousness under § 103, on the other hand, allows for the limitations to be present 
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doorknob when inventor A has already invented a clay doorknob? Clearly, the two 
are not the same invention because each is made of a different material.6 However, 
under U.S. patent law, such a minor or “obvious” variation between inventor A’s clay 
doorknob and inventor B’s metallic doorknob makes the latter unworthy of patent 
protection.7 When courts find that patent claims are invalid as obvious by improperly 
lowering the standard for non-obviousness under § 103, the incentive that the patent 
system attempts to promote is disturbed, and for pharmaceutical manufacturers in 
particular the motivation to innovate and develop new drugs is reduced.8
 In Bayer Schering Pharma AG v. Barr Laboratories, Inc., the U.S. Court of Appeals 
for the Federal Circuit considered the question of whether a pharmaceutical company’s 
patent claims covering the invention of an oral contraceptive drug were invalid as 
obvious under § 103.9 The court applied a test commonly known as the “obvious to 
try” test as a threshold matter in determining the patent’s validity and affirmed the 
opinion of the U.S. District Court for the District of New Jersey. The district court 
found the patent’s claims to be obvious under § 103 and therefore held that the patent 
was invalid.10 The Federal Circuit found that the information available to the public at 
the time the patent was developed, also known as the “prior art,”11 led the Plaintiff to 
reach a crossroads where the Plaintiff had to choose between two “viable options” that 
might work.12 However, the court failed to find that any of the available viable options 
were predictable solutions with “anticipated success,” as required by the U.S. Supreme 
in multiple analogous sources which were available to a person having ordinary skill in the art at the 
time the invention was made. Id. at 745–46.
6. See Hotchkiss v. Greenwood, 52 U.S. 248, 265 (1850).
7. Id. The court in Hotchkiss held a doorknob patent invalid because, although it was a novel idea, “there 
was an absence of that degree of skill and ingenuity, which constitute essential elements of every 
invention.” Id. at 267. However, the Hotchkiss test left great ambiguities. Law of Intellectual 
Property, supra note 1, at 746. The 1952 Patent Act, construing § 103, clarified the “invention” 
requirement by implementing the condition of non-obviousness. Id.
8. Of the many fields in which patents offer protection, the pharmaceutical industry is one where most 
experts believe that patent protection is necessary. John R. Thomas, Pharmaceutical Patent Law 
4 (2005). It has been estimated that roughly 60% of the pharmaceuticals developed would not exist 
without the incentives provided by patent protection. Edwin Mansfield, Patents and Innovation: An 
Empirical Study, 32 Mgmt. Sci. 173, 175 (1986).
9. 575 F.3d 1341 (Fed. Cir. 2009). 
10. Id. at 1343. This analysis has typically required that “there is a design need or market pressure to solve 
a problem . . . there are a finite number of identified [and] predictable solutions, [and that] a person of 
ordinary skill in the art has good reason to pursue the known options within his or her technical grasp.” 
Id. at 1347 (citing KSR Int’l Co. v. Telef lex, Inc., 550 U.S. 398, 420 (2007)). 
11. Courts have defined the scope of prior art for a non-obviousness inquiry to include all of the materials 
that could be considered relevant in determining novelty and statutory bar issues. However, for non-
obviousness, the prior art must originate within an “analogous art.” This includes a technical discipline 
relevant to the claimed invention. Thomas, supra note 8, 144–45.
12. The court held that “a person having ordinary skill in the art has reached a crossroads where he must 
choose between two known options: delivery of micronized drospirenone by a normal pill following the 
spirorenone analogy in the Krause series, or delivery of drospirenone by an enteric-coated pill following 
the Nickisch teaching that the drug needs to be protected from the stomach.” Bayer, 575 F.3d at 1350. 
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Court’s obvious to try test.13 In KSR International Co. v. Teleflex Inc., the Supreme 
Court held that an invention that is obvious to try can be unpatentable as obvious 
under § 103 when, through a combination of elements or a course of conduct, a person 
of ordinary skill in the art has available a “finite number of identified, predictable 
solutions,” which would lead that person to “anticipated success.”14
 This case comment contends that the Federal Circuit erred in its obvious to try 
analysis by not properly applying the “predictable solutions” element of the obvious to 
try test. The Federal Circuit’s predictable solutions analysis required only that prior 
art lead a person skilled-in-the-art15 to viable options, instead of properly requiring 
that the prior art lead a person skilled-in-the-art to anticipated success.16 The 
majority’s analysis strays drastically from Supreme Court precedent, which requires a 
finding that the prior art would lead to anticipated success and not merely to viable 
options. The court’s decision could have adverse consequences for future drug 
development because the incentive for drug manufacturers to invest in research and 
development will be reduced if the manufacturer is not confident that an issued 
patent will be upheld if challenged in court.17
 A. Background of Bayer Schering Pharma AG v. Barr Laboratories, Inc.
 Plaintiff Bayer Schering Pharma AG, a pharmaceutical company involved in 
drug research and development, produces the daily oral contraceptive Yasmin.18 The 
active ingredient of Yasmin is drospirenone, which inhibits ovulation.19 Drospirenone, 
however, also has the additional—and highly desirable—ability to reduce bloating 
and acne.20 In formulating the appropriate use of drospirenone as an oral contraceptive, 
Bayer faced two critical challenges.21 First, drospirenone is poorly water-soluble, 
which means that when taken orally, little drospirenone will be absorbed in the blood 
stream, where it is needed in order to be active on the body.22 Second, drospirenone 
13. Id. at 1349. In addition, the dissent reasoned that “[t]he district court stated that micronization was a 
‘viable’ option, [h]owever, ‘viability’ is not the standard.” Id. at 1351 (Newman, J., dissenting).
14. 550 U.S. 398, 421 (2007). 
15. According to § 103, the assessment of non-obviousness must be from the perspective of a “person 
having ordinary skill in the art.” 35 U.S.C. § 103(a) (2006). Courts have interpreted “person having 
ordinary skill in the art” to mean “what a hypothetical ordinary skilled artisan would have gleaned from 
the cited references at the time that the patent application leading to the . . . patent was filed.” Amazon.com, 
Inc. v. Barnesandnoble.com, Inc., 239 F.3d 1343, 1364 (Fed. Cir. 2001).
16. Bayer, 575 F.3d at 1348.
17. The motivation for researchers to develop new drug formulations will be reduced if inventors will not be 
able to enforce the exclusion rights they were granted. Because the pharmaceutical industry relies heavily 
on patent protection, the result could be that the developers reduce funding for development.
18. Bayer, 575 F.3d at 1343.
19. Id.
20. Id. (citing these additional qualities as leading to the drug’s success).
21. Id.
22. Id. The amount of active drug absorbed into the body’s bloodstream is called the “bioavailability.” Id.
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is an acid-sensitive substance that undergoes a rapid molecular structure rearrangement 
process in the stomach, called isomerization,23 resulting in the loss of the drug’s 
desired anti-bloating qualities.24 Prior art sources, however, disclosed several 
techniques for overcoming each of the individual challenges that Bayer faced, but 
none offered a solution for both challenges together.25
 The De Castro reference, for example, is a prior art source that discloses a process 
called micronization, whereby the surface area of the drug is increased. This process 
can be used on poorly water-soluble drugs as a method to increase the amount of the 
drug that will be absorbed by the body.26 But although this technique enables better 
absorption, it also makes the drug more sensitive to acid, which is problematic for 
substances such as drospirenone that are already acid-sensitive.27 Additionally, 
another prior art source, known as the Nickisch reference, discloses that micronizing 
drospirenone would increase its exposure to the body’s stomach acid, thereby 
increasing isomerization and causing the drug to lose the anti-bloating qualities.28 
Thus, although micronization may remedy the water solubility problem, it was 
known to further aggravate problems relating to acid sensitivity.
 Another prior art source consisted of experiments performed by Dr. Werner 
Krause.29 Krause disclosed the effects of both drospirenone and a similar compound 
called spirorenone.30 Krause’s experimentation with drospirenone was limited to in 
vitro studies—experiments which are conducted in a controlled setting without 
23. Acid-sensitive compounds undergo a process called isomerization when they reach the stomach’s acid, 
whereby the chemical’s molecular structure rearranges. Id. During isomerization, the stomach’s acid 
catalyzes a reaction that rearranges the molecular structure of the substance. Id. The resulting substance 
is called an isomer. Id.
24. During isomerization of drospirenone, the chemical’s molecular structure is rearranged, causing a loss 
in the anti-bloating qualities and a reduction in the absorption rate of drospirenone into the blood 
stream. Id. After drospirenone goes through isomerization, the resulting isomer is non-
antimineralocorticoidal. Id. The resulting effect leaves the substance without its desired anti-bloating 
diuretic qualities. Id. In designing methods to control this “isomerization” effect, Bayer scientists also 
were required to have the drug’s bioavailability meet the standards required for oral contraceptives. 
Id. at 1344.
25. See id. at 1344–45.
26. “Micronization” is a technique commonly used by drug developers to combat similar poorly water-
soluble compositions. See id. at 1343. Micronization increases the surface area of the drug, ensuring a 
faster dissolution rate so that all of the drug will dissolve, thus increasing the drug’s bioavailability. 
Id. at 1344. Currently, all oral contraceptives use micronization to increase bioavailability. Id. 
27. Id. at 1344.
28. During prosecution with the U.S. Patent and Trademark Office (USPTO), the patent examiner allowed 
the claims because the Nickisch reference “taught that micronizing drospirenone would increase its 
exposure to the highly acidic environment of the stomach, which would result in increased isomerization.” 
Id. at 1345. The patent examiner considered this prior art reference to teach away from micronizing 
drospirenone because it would lead to undesired results. See id.
29. Id. at 1344.
30. Spirorenone metabolizes into drospirenone when consumed. Id.
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living organisms.31 Krause, however, experimented in vivo, on living organisms, with 
spirorenone.32 Bayer scientist Dr. Johannes Tack decided that the Krause studies 
involving in vivo testing of spirorenone provided little information about the practice 
of drospirenone in vivo.33 Thus, he conducted his own in vitro experiments of 
drospirenone, which yielded the undesired finding that drospirenone undergoes rapid 
isomerization.34
 Prior art sources also disclose a technique called “enteric coating,” which is used 
to control acid sensitivity.35 When a drug is delivered via an enteric coating, it is 
surrounded by a pH-sensitive film that enables the drug to dissolve only while in the 
lower intestine, where it is less acidic than in the stomach.36 Dissolving in a less 
acidic area of the body results in lower isomerization. This enables drospirenone to 
maintain its anti-bloating qualities, which would have been a concern according to 
the Nickisch reference and the Krause teaching.37 Adding enteric coating to a drug, 
however, can lead to drawbacks, including: a possibly reduced ability to be absorbed 
into the bloodstream, delayed response of the drug on the body, and uncertain 
patient-to-patient outcomes.38 Therefore, although enteric coating could have 
controlled drospirenone’s acid sensitivity problems, it may have rendered the drug 
inactive in the body. Furthermore, a prior art source called the Hargrove reference 
concluded that not all acid-sensitive drugs require enteric coating.39
31. Id. In vitro studies are not performed on living organisms. See Merriam-Webster’s Dictionary 
(defining in vitro as “outside the living body and in an artificial environment”), available at http://www.
merriam-webster.com/medlineplus/in%20vitro.
32. Id. In vivo studies are performed on living organisms. See Merriam-Webster’s Dictionary (defining 
in vivo as “in the living body of a plant or animal”), available at http://www.merriam-webster.com/
medlineplus/in%20vivo.
33. Id. Dr. Tack consulted the research conducted by Dr. Krause, a fellow Bayer scientist, to gain insight 
into the bioavailability of poorly water-soluble substances and acid sensitivity issues of a similar 
compound, spirorenone. Id. at 1343–45.
34. Id. at 1345. As a consequence of rapid isomerization, there was a “clear reduction of bioavailablity” of 
the substance to be absorbed by the body. Id. Tack’s conclusion followed the standard known at the time 
to scientists who faced similar issues, and recommended that all further studies be performed by using 
drospirenone “with an enteric-coated formulation” so as to reduce the isomerization effect and increase 
the bioavailabilty of the drug. Id. These findings and conclusions were reconfirmed even five years later 
when Bayer conducted more in vitro studies. Id. at 1344–45.
35. Id. at 1344.
36. Id.
37. Id. at 1343–45.
38. Id. at 1344.
39. Hargrove was a study that included the use of progesterone. Id. at 1348. Progesterone, however, is not 
an acid-sensitive substance like drospirenone. Id.
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 Another available prior art source, called the Robert Aulton treatise, examines 
the relationship between in vitro experiments and in vivo experiments.40 Aulton 
discloses that:
dissolution rate data[,] when combined with solubility . . . provide an insight 
to the formulator into the potential in vivo absorption characteristics of a 
drug. However, in vitro tests only have significance if they can be related to in 
vivo results. Once such a relationship has been established, in vitro dissolution 
tests can be used as a quality control test.41
Additionally, Aulton agreed with the De Castro reference that micronization is an 
effective technique to be used with poorly water-soluble drugs, but makes no reference 
to acid-sensitive drugs and the problems that micronization can cause in further 
aggravating the acid sensitivity concern.42
 In 1988, Bayer conducted in vivo experiments to determine the measurement 
and rate of the therapeutically active form of enteric-coated drospirenone on the 
body, or its “absolute bioavailability.”43 The company tested the effects of administering 
drospirenone through an intravenous injection, an enteric-coated pill, and a 
micronized pill.44 The results unexpectedly showed that the micronized pill resulted 
in the same bioavailability as the enteric-coated pill.45 Bayer filed an application for a 
patent where the application’s claims were first rejected by the USPTO on grounds 
40. Id. at 1349. The Federal Circuit in Cross v. Iizuka held that both in vitro and in vivo studies would 
satisfy the utility requirement set forth in § 101. 753 F.2d 1040 (Fed. Cir. 1985). If the data are 
reasonably correlated with the particular pharmacological or therapeutic utility requirement claimed in 
the patent application, then a satisfactory demonstration of patent utility is shown. U.S. Patent & 
Trademark Office, U.S. Dep’t of Commerce, Manual of Patent Examining Procedure § 
2107.03 (8th ed. 2001). 
41. Bayer, 575 F.3d at 1348 (citing Robert Aulton, Pharmaceutics: The Science of Dosage Form 
Design 9 (1988)).
42. Aulton does not disclose the definite outcome when micronizing a poorly water-soluble substance that 
is also acid-sensitive. Bayer, 575 F.3d at 1348. In fact, Aulton teaches that the outcome would be 
uncertain. Id. Aulton also disclosed that micronizing a poorly water-soluble substance—such as 
drospirenone—may sometimes result in increased isomerization, but can also result in decreased 
isomerization. Id.
43. Id. at 1345. The “absolute bioavailability” would have been determined by comparing the results of the 
enteric-coated pill and the intravenous injection. Id.
44. Id. Experiments conducted to determine the absolute bioavailability of an enteric-coated substance 
routinely involve only comparing the results of the enteric-coated pill with the results of the intravenous 
injection. Tack chose to add the non-routine element of the normal micronized pill as well. Id. 
45. Id. Tack, along with the rest of the Bayer scientists involved, expected the results to show that the 
enteric-coated tablet produced a lower bioavailability than the intravenous injection—which it did. Id. 
However, no one expected that the normal pill would deliver the same bioavailability as the enteric-
coated pill. Id. It was expected, for good reason, that the enteric-coated pill would produce a higher 
bioavailability than the normal pill because the normal pill should have been dissolved more in the 
stomach where the acid would cause a higher rate of isomerization. Id. This finding was inconsistent 
with the Nickisch reference prior art, which indicated that there would be a clear reduction of the 
bioavailability of drospirenone when administered in a normal (micronized) pill because micronizing 
the compound would increase its exposure to the stomach’s highly acidic environment. Id.
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that the claims were obvious in view of the De Castro reference, which taught that 
poorly soluble drugs can be micronized in order to increase their absorption by the 
body.46 However, Bayer responded by indicating that the Nickisch reference “teaches 
away”47 from the micronizing of acid sensitive drugs and, therefore, the patent claims 
could not be obvious.48 The USPTO considered Bayer’s response and allowed the 
claims.49 The USPTO issued Bayer U.S. Patent No. 6,787,531 (“Yasmin patent”) for 
Yasmin on September 7, 2004.50
 Defendant Barr Laboratories, Inc. is a generic pharmaceutical company51 that 
filed an Abbreviated New Drug Application (ANDA) with the Food and Drug 
Administration (FDA) seeking approval to market a generic form of Yasmin.52 When 
Bayer learned of Barr’s FDA application, it filed a patent infringement suit against 
Barr for infringing their Yasmin patent.53 Barr argued that it should be permitted to 
46. Id.
47. According to the Federal Circuit, “[a] reference may be said to teach away when a person of ordinary 
skill, upon reading the reference, would be discouraged from following the path set out in the reference, 
or would be led in a direction divergent from the path that was taken by the applicant.” In re Kubin, 561 
F.3d 1351, 1357 (Fed. Cir. 2009); In re Gurley, 27 F.3d 551, 553 (Fed. Cir. 1994).
48. Nickisch taught that micronizing drospirenone would result in increased isomerization because of 
increased exposure to the stomach’s acid. Bayer, 575 F.3d at 1345, 1349.
49. Upon allowing the claims, the examiner stated: “The micronized drospirenone will be degraded even more 
rapidly because the micronization of drospirenone expose[s] the drug particles in the stomach . . . . Therefore, 
to formulate an oral dosage form[] containing the drospirenone particles, which exposed to the gastric 
environment upon dissolution, would be un[o]bvious in view of the data presented . . . .” Id. at 1345.
50. Id. at 1343, 1345. The claims of the patent are covered by representative claim 1 which states:
A pharmaceutical composition comprising[: a)] from about 2 mg to about 4 mg of 
micronized drospirenone particles, about 0.01 mg to about 0.05 mg of 17.alpha.-
ethinyllestradiol, and one or more pharmaceutically acceptable carriers, [b)] the composition 
being in an oral dose form exposed to the gastric environment upon dissolution, [c)] and 
the composition being effective for oral contraception in a human female.
 Id. at 1345–46. 
51. Id. at 1346. Barr Laboratories is a subsidiary of Teva Pharmaceutical Industries. Teva and Ortho McNeil-
Janssen Settle Oral Contraceptive Lawsuit; Bayer Patent Declared Invalid, World Generic Markets 
(ESPICOM Bus. Intelligence Ltd.), Aug. 21, 2009.
52. Bayer, 575 F.3d at 1346. It is very common for generic companies such as Barr to file ANDAs with the 
FDA to seek approval to market generic forms of patented drugs. The Drug Price Competition and Patent 
Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, contains provisions which 
enable generic manufacturers to obtain FDA approval to market a drug that is already patented by another 
pharmaceutical company. The Hatch-Waxman Act enabled generic manufacturers to begin developing a 
generic form of an approved drug during the life of a patent, as long as the development is in compliance 
with FDA regulations. ANDAs permit generic companies to use the safety and efficiency data, developed 
by the original manufacturer, for the purpose of FDA review. Thomas, supra note 8, at 12–15.
53. Bayer, 575 F.3d at 1346. The Hatch-Waxman Act requires the generic manufacturer applying for the 
ANDA to notify the patent holder that it has requested FDA approval to manufacture and market the 
new drug. Under § 271(e)(2), when a generic manufacturer files an ANDA they have performed a 
“somewhat artificial” act of patent infringement. Therefore, the patent holder may raise a patent 
infringement complaint in a federal district court. Thomas, supra note 8, at 16 (citing 35 U.S.C. 
§ 271(e)(2) (2006)).
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market a generic form of the drug Yasmin without infringing on Bayer’s claims 
because the patent’s claims are invalid due to obviousness or, in the alternative, were 
not infringed.54
 B. The Bayer Court’s Legal Analysis
 The district court held the Yasmin patent claims to be invalid as obvious under § 
103 after applying the obvious to try test.55 The court concluded that “it would have 
been obvious to a person having ordinary skill in pharmaceutical formulation to try a 
normal [micronized] pill in formulating drospirenone as an oral contraceptive.”56 
The court rejected Bayer’s argument that Nickisch “teaches away” from micronizing 
drospirenone, and explained that a person skilled-in-the-art would recognize 
Nickisch’s shortcomings because Aulton teaches to “verify whether drospirenone 
absorbed or isomerized with precise in vivo and in vitro testing.”57 Specifically, the 
court explained that Aulton teaches not to accept in vitro results without correlating 
the data with in vivo testing.58 Thus, the court reasoned that Bayer should not have 
conclusively relied on the Nickisch and Krause in vitro disclosures, but rather should 
have conducted its own in vivo tests to verify the effects of micronizing drospirenone 
in vivo.59 The court even acknowledged Aulton’s silence regarding acid-sensitive 
drugs, but “concluded that a person having ordinary skill would have seen 
[micronization] as a viable option.”60 The court also determined that Krause should 
have led Bayer to believe that drospirenone—like spirorenone—may absorb in vivo, 
but isomerize in vitro, even though they are two different substances.61 Furthermore, 
the court found that micronizing drospirenone was a viable option in light of 
Hargrove, even though Hargrove’s test involved a different drug that is not acid-
sensitive like drospirenone.62
 On appeal, the Federal Circuit affirmed the district court’s holding that Bayer’s 
patent claims were obvious under § 103.63 The Federal Circuit also applied the obvious 





59. See id. 
60. Id. at 1348.
61. Id. at 1349.
62. Id. at 1348. On June 24, 2008, Barr entered into a licensing agreement with Bayer to distribute a generic 
form of Yasmin. Bayer supplied Barr with the generic form, which Barr marketed under the title 
“Ocella.” Barr began distribution of Ocella in July 2008. Teva and Ortho McNeil-Janssen Settle Oral 
Contraceptive Lawsuit; Bayer Patent Declared Invalid, World Generic Markets (ESPICOM Bus. 
Intelligence Ltd.), Aug. 21, 2009; Elizabeth Jones, Appeals Court Affirms Invalidity of Yasmin Patent, 
Generic Line (FDA News), Aug. 19, 2009, Vol. 26 No. 16.
63. Bayer, 575 F.3d at 1350.
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to try test and found that the “predictable solutions” element of the test was satisfied 
merely because Bayer had two known viable options to consider.64 The court reasoned 
that the two known options available to Bayer were “delivery of micronized drospirenone 
by a normal pill following the spirorenone analogy in the Krause series, or delivery of 
drospirenone by enteric-coated pill following the Nickisch teaching that the drug needs 
to be protected from the stomach.”65 Thus, the court found that “[b]ecause the selection 
of micronized drospirenone in a normal pill led to the result anticipated by the Krause 
series, the invention would have been obvious.”66 However, in finding that the prior art 
would lead to viable options, neither the district court nor the Federal Circuit found that 
the prior art would lead a person skilled-in-the-art to “anticipated success.”67 In other 
words, the Federal Circuit failed to demonstrate the second element of the obvious to 
try test, which is that the solutions not only be of a “finite number” and “identified,” but 
also that the solutions be “predictable,” the latter being accomplished by a showing that 
the identified solutions will result in anticipated success if attempted.68
 Judge Newman, in dissent, argued that the proper application of the obvious to 
try test requires a finding that the prior art lead to “predictable solutions,” and that 
the “predictable solutions” standard is satisfied only when the prior art leads a person 
skilled-in-the-art to “anticipated success.”69 She further contended that the prior art 
“teaches away” from micronizing acid-sensitive chemicals because doing so will 
accelerate the degradation of the pill.70 The dissent asserted the irrelevance of Krause, 
reasoning that Krause could not have led a person having ordinary skill in the art to 
anticipated success because Krause involved a chemical, which was not acid-
sensitive.71 According to the dissent’s reasoning, nothing in the prior art suggests the 
likelihood of success from the ingestion of uncoated micronized drospirenone.72 
Instead, the dissent argued that the prior art taught of the likelihood of failure in 
such an experiment.73 Judge Newman concluded that the proper application of the 




67. See id. at 1347–48.
68. See id. at 1351.
69. Judge Newman argued, “The Court in KSR . . . explained that the standard for obvious to try is whether 
there was a ‘reasonable expectation of success’ at the time.” Id. (Newman, J., dissenting).
70. See id. at 1350–51.
71. See id. at 1351.
72. See id.
73. Id. Judge Newman argued that “[n]othing in the prior art teaches the likelihood of success of ingestion 
of uncoated micronized drospirenone; what is taught is the likelihood of failure.” Id.
74. See id. In dissent, Judge Newman stated that “‘viability’ is not the standard. ‘Viability’ implies that the 
experiment may or may not succeed. What the law requires is not guesswork, not dumb luck, but a 
reasonable degree of predictability of success.” Id.
409
nEW YOrK LaW sChOOL LaW rEViEW VOLUME 55 | 2010/11
rather, it requires that the prior art lead to both viable options and anticipated 
success.75 Furthermore, the dissent acknowledged that if the prior art “teaches away” 
from a result and there is no indication of a likelihood of success, then there cannot 
be anticipated success leading to predictable solutions.76
 This case comment contends that the Federal Circuit incorrectly applied the 
obvious to try test in finding obviousness under § 103. Specifically, the Federal 
Circuit incorrectly applied the “predictable solutions” element of the test by requiring 
that the prior art lead a person skilled-in-the-art only to certain viable options that 
might work, instead of requiring that the prior art lead a person skilled-in-the-art to 
anticipated success, which is mandated by Supreme Court precedent.77 Part II of this 
case comment discusses the origins of the obvious to try test and its elements. Part 
III of this case comment discusses the court’s f lawed application of the “predictable 
solutions” element of the obvious to try test and two ways in which it was inconsistent 
with Supreme Court precedent. Specifically, Part III.A analyzes how the Federal 
Circuit incorrectly devalued prior art that “taught away” from desired outcomes even 
in the absence of conflicting teachings. Part III.B of this case comment discusses 
how the Federal Circuit erroneously relied on prior art references that would only 
lead to experimentation with unknown results to find that the “predictable solutions” 
element of the obvious to try test was satisfied. Part IV concludes.
ii. Origins Of thE ObViOUs tO trY tEst
 In KSR International Co. v. Teleflex Inc., the Supreme Court articulated the 
obvious to try test to clarify certain circumstances in which a patent may be invalid 




77. The court held that the predictable solution standard was satisfied because the prior art led Bayer to 
“reach a crossroad” where it would have to choose between two known viable options that might work. 
Id. at 1350. The two viable options were “delivery of micronized drospirenone by a normal [micronized] 
pill following the spirorenone analogy in the Krause series, or delivery of drospirenone by an enteric-
coated pill following the Nickisch teaching that the drug needs to be protected from the stomach.” Id. 
at 1350. However, the court failed to find that either viable option available to Bayer contained 
anticipated success. As Judge Newman argued in dissent, the Supreme Court requires that the viable 
options have a reasonable expectation of success. Id. at 1351 (Newman, J., dissenting).
78. 550 U.S. 398 (2007); 35 U.S.C. § 103(a) states that:
[a] patent may not be obtained . . . if the differences between the subject matter sought 
to be patented and the prior art are such that the subject matter as a whole would have 
been obvious at the time the invention was made to a person having ordinary skill in 
the art to which said subject matter pertains. Patentability shall not be negatived by the 
manner in which the invention was made.
 Id. In KSR, the Supreme Court interpreted the statute with regards to the obviousness of a patent 
claiming the use of an electronic sensor on an automobile pedal with a fixed pivot point. The Supreme 
Court held the patent invalid as obvious, reasoning that the patent was merely a combination of related 
prior art that anticipated predictable results. Specifically, the Court held that “[t]he combination of 
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[w]hen there is a design need or market pressure to solve a problem and there 
are a finite number of identified, predictable solutions, a person of ordinary skill 
has good reason to pursue the known options within his or her technical grasp. 
If this leads to the anticipated success, it is likely the product not of innovation 
but of ordinary skill and common sense. In that instance the fact that a 
combination was obvious to try might show that it was obvious under § 103.79
Thus, KSR provides that the obvious to try test may lead to a finding of obviousness 
under § 103 when two elements are satisfied.80 First, there must be a finite number 
of identified solutions.81 Second, those finite number of identified solutions must be 
“predictable solutions.”82 This second element is satisfied when the prior art leads a 
person skilled-in-the-art to anticipated success; in other words, there must be a 
reasonable expectation of success in order for the second element to be satisfied.83 
The Supreme Court did not articulate or endorse a standard under which obviousness 
may be based solely on the patentable alternative being merely a viable option—that 
is, an option that might work.84
 The Supreme Court in KSR adopted its reasoning from the Federal Circuit 
decision of In re O’Farrell, where the Federal Circuit described two situations in 
which a finding that something is “obvious to try” is insufficient to establish 
obviousness under § 103.85 The first situation explains KSR’s first element that there 
be a “finite number of identified solutions,” which was based on the holding in 
O’Farrell that § 103 obviousness is not found where
what would have been “obvious to try” would have been to vary all parameters 
or try each of numerous possible choices until one possibly arrived at a 
successful result, where the prior art gave either no indication of which 
parameters were critical or no direction as to which of many possible choices 
is likely to be successful.86
 The other situation described in O’Farrell explains the second required element, 
specifically, that those “finite number of identified solutions” also be “predictable 
familiar elements according to known methods is likely to be obvious when it does no more than yield 
predictable results.” 550 U.S. 398, 416 (2007) (emphasis added). 





84. See Brief of Amicus Curiae American Intellectual Property Law Association in Support of Neither 
Party at 4, Bayer Schering Pharma AG v. Barr Lab., Inc., 575 F.3d 1341 (Fed. Cir. 2009) (No. 2008-
1282), 2009 WL 3393593 [hereinafter Brief for AIPLA].
85. See KSR, 550 U.S. 398, 415 (2007) (citing In re O’Farrell, 853 F.2d 894, 903 (1988)).
86. Id.
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solutions.”87 As the majority in Bayer correctly pointed out, citing O’Farrell, § 103 
obviousness is not found where “what was ‘obvious to try’ was to explore a new 
technology or general approach that seemed to be a promising field of experimentation, 
where the prior art gave only general guidance as to the particular form of the claimed 
invention or how to achieve it.”88 Therefore, as the Federal Circuit acknowledged in 
O’Farrell and in Bayer, the Supreme Court’s obvious to try standard—as expressed in 
KSR—is not met for purposes of finding obviousness under § 103 when the prior art 
supplies only “general guidance.”89
iii. thE COUrt’s fLaWEd appLiCatiOn Of thE ObViOUs tO trY standard
 The Federal Circuit incorrectly applied the “predictable solutions” element of the 
test by requiring that the prior art lead a person skilled-in-the-art to viable options, 
i.e., those that might work, instead of requiring that the prior art lead a person skilled-
in-the-art to anticipated success. Its analysis of that element was f lawed in two ways. 
First, the court incorrectly devalued prior art that “taught away” from the desired 
result without finding a conflicting prior art reference. Second, the court erroneously 
relied on prior art that would lead a person only to experimentation with unknown 
results. Each of these errors is discussed in turn.
 A. Devalutation of Prior Art
 The Federal Circuit’s application of the predictable solution element of the 
obvious to try test was f lawed because the court incorrectly devalued prior art that 
“taught away” without finding a conflicting prior art reference.90 The Federal Circuit 
87. Bayer, 575 F.3d at 1347 (“This expresses the same idea as the KSR requirement that the identified 
solutions be ‘predictable.’” (quoting O’Farrell, 853 F.2d at 903)).
88. Id.; O’Farrell, 853 F.2d at 903.
89. O’Farrell, 853 F.2d at 903.
90. The “predictable solutions” element cannot be satisfied where the prior art “teaches away” from a 
particular solution because if it is “teaching away” then it cannot be supplying more than a “general 
guidance” as the particular form of the claimed invention or how to achieve it successfully. The Federal 
Circuit defined prior art that “teaches away” from a particular result in In re Gurley as “when a person of 
ordinary skill, upon reading the reference, would be discouraged from following the path set out in the 
reference, or would be led in a direction divergent from the path that was taken by the applicant.” 27 
F.3d 551, 553 (Fed. Cir. 1994). Therefore, if a prior art reference is discouraging a person skilled-in-the-
art from following a particular path, a person skilled-in-the-art cannot, at the same time, be provided 
more than a “general guidance” to a successful result unless there is some other prior art reference which 
is inconsistent with the reference that “teaches away” and does provide a correct guidance to the inventor. 
In Gurley, the court mentions that each prior art source can have a particular degree of teaching away. 
Id. In other words, in order for the identified solution to also be predictable where there are prior art 
references that are “teaching away,” there must be another reference conflicting with the findings of the 
references that “teaches away” in order to provide sufficient guidance to a person skilled-in-the-art 
toward a successful outcome. See In re Young, 927 F.2d 588 (Fed. Cir. 1991). “When prior art contains 
apparently conflicting references, the Board must weigh each reference for its power to suggest solutions 
to an artisan of ordinary skill . . . . The Board, in weighing the suggestive power of each reference, must 
consider the degree to which one reference might accurately discredit another.” Id. at 591. The 
importance of secondary considerations such as the presence of prior art that “teaches away” has been 
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acknowledged that Nickisch teaches that micronizing drospirenone would increase 
its exposure to the stomach’s acid, thereby increasing isomerization and causing the 
drug to lose its anti-bloating qualities.91 Therefore, if Bayer had followed Nickisch, it 
would have expected that delivery of drospirenone in a micronized form would 
provide an unsuccessful or undesired result. Nonetheless, the Federal Circuit 
disregarded the fact that Nickisch would lead Bayer away from the desired result and 
instead held that the predictable solution element was satisfied.92
 In order for the Federal Circuit to have properly depreciated the value of the 
Nickisch teachings, the court would have had to simultaneously find an inconsistent 
teaching in another prior art source.93 A proper application of the “predictable 
solutions” element under KSR would demonstrate that Nickisch “teaches away” from 
a successful result and therefore cannot satisfy the “predictable solutions” element 
because it cannot both lead a person toward a divergent path and, at the same time, 
offer more than a general guidance as to a successful result without another reference 
present to conflict with Nickisch. Therefore, because the Federal Circuit failed to 
find any prior art references that were inconsistent with Nickisch, the court incorrectly 
devalued Nickisch.94
 B. Erroneous Reliance on Prior Art
 The second way in which the Federal Circuit’s application of the “predictable 
solutions” element was f lawed was that the court erroneously relied on prior art that 
would lead a person only to experimentation with unknown results.95 The court 
long recognized by the Federal Circuit and was made explicit in Stratoflex, Inc. v. Aeroquip Corp., 713 
F.2d 1530 (Fed. Cir. 1983). In Stratoflex, the Federal Circuit stated that
[i]t is jurisprudentially inappropriate to disregard any relevant evidence on any issue in 
any case, patent cases included. This evidence rising out of the so-called “secondary 
considerations” must always when present be considered en route to a determination of 
obviousness . . . . En route to a conclusion of obviousness, a court must not stop until all 
pieces of evidence on that issue have been fully considered and each has been given its 
appropriate weight . . . . It is an error to exclude that evidence from consideration.
 Id. at 1538–39. 
91. Bayer, 575 F.3d at 1346.
92. See id. at 1350.
93. Id. at 1346–47.
94. Id. at 1350.
95. Under the Federal Circuit’s loose application of the “predictable solutions” requirement, certain patent 
claims will be rendered invalid as obvious if a challenging party can simply demonstrate that the prior 
art leads a person skilled-in-the-art to viable known options to consider without demonstrating that those 
identified viable options are also “predictable solutions.” Id. at 1349–50. The problem with this standard 
is that it falls short of the Supreme Court’s heightened requirement that the prior art lead a person 
skilled-in-the-art to anticipated success and enables the court to rely on prior art that only leads a person 
skilled-in-the-art to experimentation with unknown results. If the prior art only leads a person skilled-
in-the-art to experimentation with unknown results, then it is difficult for a court to demonstrate that 
the prior art also provides more than a “general guidance” as required under the “predictable solutions” 
element. Judge Newman, in dissent, articulated this problem by stating “[t]he court rules that the 
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acknowledged, but improperly discredited, the fact that Krause leads only to 
experimentation in order to find the results of micronizing drospirenone because 
Krause uses a different substance with different qualities from drospirenone.96 
According to the majority’s reasoning, the in vivo results of drospirenone are material 
in determining the proper delivery form of the substance.97 The limited Krause in 
vitro experiments on drospirenone left Bayer scientists with uncertainty as to how 
drospirenone would react in vivo, and so further experimentation was necessary for 
Bayer to properly determine the behavior of drospirenone on the body.98 When prior 
art teaches that a result is unknown, it is likely that it will not lead a person skilled-
in-the-art to anticipated success because the prior art does not offer guidance toward 
a successful result. Krause only discloses information regarding the in vivo use of 
spirorenone, which provides little information about the proper delivery form of 
drospirenone in vivo.99
iV. COnCLUsiOn
 The Federal Circuit’s application of the KSR obvious to try test in Bayer was 
f lawed because it only required that the prior art merely lead to viable options that 
might work as sufficient to satisfy the predictable solution element set forth in the 
test.100 However, as the Supreme Court pointed out in KSR, a predictable solution 
under the test requires that the prior art lead not merely to viable options, but that it 
lead to anticipated success.101 In Bayer, the Court held that because Bayer had two 
known viable options available, Bayer’s patent was a “predictable solution,” without 
scientists should have ‘tried’ that which they believed would fail, and that when they eventually did try 
this unlikely formulation, and it succeeded, it was obvious to do so.” Id. at 1351 (Newman, J., dissenting). 
If the outcome of experimentation was unknown at the time the invention was made, then it is difficult 
to find that there is a reasonable expectation of success. Finding that the patent is obvious under these 
circumstances is likely to condone the use of hindsight analysis by the courts. Brief for AIPLA, supra 
note 80, at 8–9; see also Gurley, 27 F.3d at 553. 
96. Bayer argued that these two chemicals are so different that the former could isomerize at a rate of 40% 
faster than the latter. Yet still the court explained that in light of Krause, “a drug formulator having 
ordinary skill had a viable known option to consider with micronized, unprotected drospirenone.” Bayer, 
575 F.3d at 1349 (emphasis added).
97. According to the majority’s own reasoning, Aulton teaches not to rely solely on in vitro results. Id. at 1348, 
1350. Therefore, because Krause does not disclose any in vitro results for drospirenone, Bayer scientists 
should not have reasonably expected for it to be successful when delivered in a micronized form.
98. Id. at 1344–45, 1349. Therefore, although Krause may lead to a known option to consider, it does not 
necessarily provide more than a “general guidance” toward an anticipation of success—as required under 
the KSR predictable solution element—because experimentation is still required to resolve an 
uncertainty. The court, therefore, inappropriately assumed that a person skilled-in-the-art would rely 
on Krause as leading to a predictable solution because the court only required that Krause lead to known 
options to consider instead of properly requiring that Krause lead to anticipated success. Id. at 1349.
99. See id. at 1344–45, 49. 
100. See id. at 1348; see also KSR, 550 U.S. 398, 415 (2007).
101. 550 U.S. at 421.
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determining whether either viable option would lead to anticipated success.102 
Whether micronizing drospirenone was a viable option is not the end of the inquiry 
according to the Supreme Court’s holding in KSR.103 KSR requires more, which the 
Federal Circuit failed to find. In addition, the Supreme Court’s obvious to try test 
requires that the viable options have a reasonable expectation of success, specifically, 
anticipated success.104
 The court’s failure to satisfy the second step in its application of the “predictable 
solutions” element of the obvious to try test strays drastically from the Supreme 
Court precedent. If such a loose analysis is followed, there could be drastic effects on 
the incentives that the patent system creates. Pharmaceutical manufacturers rely 
heavily on the patent system’s incentive to invent when they invest considerable 
amounts of money in the research and development of new pharmaceuticals.105 If 
courts continue to invalidate patents, as in Bayer, the incentive for pharmaceutical 
manufacturers to invest in research and development will be reduced, thus resulting 
in fewer drugs for the public.106
102. 575 F.3d at 1347. In altering the standard to include viable options that might work, the Federal Circuit 
erroneously renders prior art that teaches away from an outcome irrelevant for an obvious to try analysis. 
Id. However, KSR, in establishing the test, required the courts to consider prior art that teaches away 
because it would likely demonstrate that the invention is not obvious. KSR, 550 U.S. at 416. Furthermore, 
the Federal Circuit inappropriately ignored clear errors made by the district court by holding that 
Hargrove provided Bayer with a predictable solution to the acid sensitivity problem, even though the 
majority acknowledged that the district court erroneously thought Hargrove taught a solution to acid 
sensitivity issues when, in fact, that prior art only teaches solutions for solubility. Bayer, 575 F.3d at 
1348. By transforming the “predictable solutions” standard to include “viable options” that might work, 
the court is essentially considering situations where experimentation is required as sufficient to 
determine obviousness even though experimentation is required to determine an unknown outcome. 
Id. 
103. Brief for AIPLA, supra note 80, at 4.
104. Id. at 4; see also KSR, 550 U.S. at 421.
105. See Thomas, supra note 8, at 2.
106. Id.
